Icatibant Aguettant (Icatibant)

Icatibant works by selectively blocking the bradykinin B2 receptor on blood‑vessel walls. By preventing bradykinin from binding, it stops the cascade that leads to vasodilation and increased vascular permeability, which are the primary drivers of the swelling seen in hereditary angioedema.

The dose of Icatibant is determined by the prescribing clinician based on the patient’s condition and clinical guidelines. Typically, a single subcutaneous injection is given at the onset of an HAE attack, and additional doses may be administered if symptoms persist, as directed by the healthcare professional.

Safety data for icatibant during pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians usually reserve its use for pregnant or nursing patients when alternative therapies are unsuitable.

To order Icatibant Aguettant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

The primary alternative to icatibant is plasma‑derived or recombinant C1‑esterase inhibitor replacement therapy. While C1‑esterase inhibitors restore the deficient protein, icatibant directly blocks the bradykinin receptor. Icatibant offers a rapid, subcutaneous option without the need for intravenous infusion, but both classes are effective and choice depends on patient preference, attack severity and clinical setting.

Icatibant should be stored in a refrigerator at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes before use.

Icatibant is administered as a subcutaneous injection, usually into the abdomen or thigh. The injection can be performed by a trained healthcare professional or, after appropriate instruction, by the patient or caregiver. Injection sites should be rotated to minimise local irritation.

The most serious adverse reactions include anaphylaxis, severe angioedema unrelated to hereditary angioedema, and sudden hypotension. Patients should be monitored after the first dose, and any signs of systemic allergic reaction or rapid blood‑pressure drop should prompt immediate medical attention.

Icatibant is contraindicated in individuals with a known hypersensitivity to icatibant or any of the excipients in the formulation. Caution is also advised for patients with severe renal or hepatic impairment, and the drug should only be used in pregnancy or lactation when the expected benefit outweighs potential risks.